DCGI approves Glenmark’s phase-I clinical trial for its novel molecule GRC 54276
The company will initiate the trial by June 2022 to determine the safety, tolerability and preliminary anti-tumour activity of the…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.